壳聚糖纳米颗粒佐剂PcrV疫苗对烧伤及脓毒症小鼠铜绿假单胞菌感染的保护效力
本研究将重组PcrV蛋白与铝佐剂及壳聚糖纳米颗粒(CS-NPs)联用制备疫苗,免疫BALB/c小鼠后行烧伤并感染铜绿假单胞菌PAO1,并在脓毒症模型中攻击。r-PcrV+Alum+Nanochitosan组IFN-γ、IL-4、总IgG、IgG1、IgG2a及调理吞噬活性均显著升高(p<0.0001),肝、脾、肾、皮肤细菌负荷明显降低,烧伤模型生存率75%、脓毒症模型87.5%。
要点
- r-PcrV+Alum+壳聚糖纳米颗粒可协同增强Th1/Th2免疫应答。
- 该配方显著降低烧伤感染小鼠内脏及皮肤细菌负荷。
- 烧伤与脓毒症模型生存率分别达75%和87.5%。
核心结论
- r-PcrV+Alum+Nanochitosan配方可诱导强保护性免疫,是抗多重耐药铜绿假单胞菌的候选疫苗。
研究设计与样本
- 临床前小鼠实验:CS-NPs经离子凝胶法制备并表征形态与电荷,BALB/c小鼠分别免疫r-PcrV+Alum+Nanochitosan、r-PcrV+Alum、r-PcrV+Nanochitosan、Nanochitosan+Alum或PBS,随后行烧伤诱导并感染铜绿假单胞菌PAO1,另设脓毒症模型攻击。
主要发现
- r-PcrV+Alum+Nanochitosan组IFN-γ、IL-4、总IgG、IgG1、IgG2a及调理吞噬活性显著高于其他实验组(p<0.0001)。
- 该组肝、脾、肾及皮肤组织细菌负荷显著降低。
- 该组烧伤模型生存率为75%,脓毒症模型生存率为87.5%。
临床怎么用
- 提示铝佐剂与壳聚糖纳米颗粒联用可增强PcrV疫苗的体液与细胞免疫,为烧伤患者抗铜绿假单胞菌感染提供候选策略。
局限性
- 原文为小鼠模型临床前研究,尚未进行临床评估;未来需探索其他佐剂组合及毒力相关抗原。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen and a major clinical concern due to its multidrug resistance and extensive virulence repertoire. In this study, recombinant PcrV protein was formulated with Alum and chitosan nanoparticles (CS-NPs) as co-adjuvants to enhance immunogenicity. CS-NPs were prepared via ionic gelation and characterized for morphology and charge. BALB/c mice were immunized with formulations containing r-PcrV + Alum + Nanochitosan, r-PcrV + Alum, r-PcrV + Nanochitosan, or Nanochitosan + Alum or PBS (control). This was followed by burn induction, after which the burn wounds were intentionally infected with Pseudomonas aeruginosa PAO1, as well as challenged in a septicemia model. Indirect ELISA was used to evaluate both humoral and cellular immune responses. Vaccine efficacy was further assessed through opsonophagocytic activity and quantification of bacterial load in internal organs and skin tissues. Mice receiving the r-PcrV + Alum + Nanochitosan formulation exhibited significantly elevated IFN-γ and IL-4 cytokine levels, higher total IgG, IgG1, and IgG2a responses, and enhanced opsonophagocytic activity compared to other experimental groups (p < 0.0001). This group also demonstrated markedly reduced bacterial loads in liver, spleen, kidney, and skin tissues, as well as superior survival rates 75% in burn and 87.5% in sepsis models, indicating strong protective immunity. The synergistic combination of Alum and Nanochitosan effectively elicited both Th1- and Th2-mediated responses, leading to improved pathogen clearance and immune balance. These findings highlight the potential of the r-PcrV + Alum + Nanochitosan formulation as a promising vaccine candidate against multidrug-resistant P. aeruginosa, a major cause of morbidity and mortality in burn patients. Future investigations should explore alternative adjuvant combinations, additional virulence-associated antigens, and clinical evaluation of this formulation to advance toward translational application.
引用
- Jafarvand Atashgah H, Haghighat S, Abdolghaffari AH, et al. Protective efficacy of a PcrV-based vaccine formulated with chitosan nanoparticles against Pseudomonas aeruginosa infection in burn and sepsis mouse models. Burns. 2026. PMID: 42114463. doi:10.1016/j.burns.2026.108033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。